# Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis

> **NCT04148898** · PHASE2 · UNKNOWN · sponsor: **Second Affiliated Hospital of Nanchang University** · enrollment: 80 (estimated)

## Conditions studied

- Leptomeningeal Metastasis
- Non-small Cell Lung Cancer
- EGFR Activating Mutation

## Interventions

- **DRUG:** Osimertinib
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT04148898
- **Lead sponsor:** Second Affiliated Hospital of Nanchang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-01
- **Primary completion:** 2021-03-01
- **Final completion:** 2021-07-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2019-11-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04148898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04148898, "Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04148898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*